iiinova — where your digital self keeps evolving

Reposted by Sherry Shen, MD

San Antonio Breast Cancer Symposium @sabcs.bsky.social · 09/09/2025

Clinical Controversies: Management of the Axilla— Giacomo Montagna, Lori Pierce, and Sherry Shen will address this topic in a special session at #SABCS25 (December 9-12). Learn more: buff.ly/ykgbF15 @sherryshenmd.bsky.social

011

Reposted by Sherry Shen, MD

Esra @esrajustesra.bsky.social · 11/06/2025

A big thank you to Dr. Mouabbi @jamouabbi.bsky.social and Dr. Shen @sherryshenmd.bsky.social for your time and wonderful presentations on lobular cancer. Thank you @graspcancer.bsky.social for organizing these sessions!

011

Sherry Shen, MD @sherryshenmd.bsky.social · 27/04/2025

Thank you @theaacr.bsky.social for inviting me to speak on integrating GLP-1RAs into clinical cancer care. Great session alongside Drs. Stephen Hursting & Rong Xu. Some data on use in cancer patients now, but so much more needed!

092

Reposted by Sherry Shen, MD

MSK Department of Medicine @mskdeptofmed.bsky.social · 26/04/2025

At #AACR25, join breast medical oncologist @sherryshenmd.bsky.social for an education session on best practices to introduce GLP1-RAs, like Ozempic, into clinical #cancer care. @mskcancercenter.bsky.social @theaacr.bsky.social Learn more: bit.ly/4jso7Ed 3:01-3:21 p.m. CT

052

Reposted by Sherry Shen, MD

Ilana Schlam @ilanaschlam.bsky.social · 13/12/2024

Wrapping up another fantastic #SABCS! Amazing, practice-changing data were presented. I’ve updated the algorithms and added key studies from the meeting— I finally ran out of space in HR+ disease! #SABCS24 @oncoalert.bsky.social

04619

Sherry Shen, MD @sherryshenmd.bsky.social · 13/12/2024

When @breastcancerdoc.bsky.social & I are unintentionally matching at our poster on T-DXd in pts with HER2-low lobular MBC. PFS 7.2m in total cohort, shorter in those with PIK3CA/AKT/PTEN muts & trend toward longer in HER2mut. More research needed in lobular BC!

2134

Sherry Shen, MD @sherryshenmd.bsky.social · 11/12/2024

First Bluesky post! EMBER-3 presented by my mentor @breastcancerdoc.bsky.social demonstrating greater mPFS as single agent vs. SOC ET in ESR1mut, and impressive benefit of imlunestrant+abema with mPFS 9.4 months, 59% had prior CDK4/6i. Novel ET + CDK4/6i switch is intriguing - ELAINE3 is enrolling!

052